FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews

FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.